Atenolol - CAS 29122-68-7
Catalog number: 29122-68-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C14H22N2O3
Molecular Weight:
266.34
COA:
Inquire
Targets:
Adrenergic Receptor
Description:
Atenolol, with antianginal and antiarrhythmic properties, it is a cardioselective beta-adrenergic blocker and used in hypertension control.
Purity:
>98.0%(T)
Appearance:
White powder
Synonyms:
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide Atenolol ICI 66082 ICI-66082 ICI66082 Tenormin Tenormine
Solubility:
Soluble to 0.3mg/mL in H2O, 18mg/mL in DMSO, 3.4 mg/mL in toethanol
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -44℃ for long term (months to years).
MSDS:
Inquire
Quality Standard:
-
Shelf Life:
2 years
Boiling Point:
508.0±50.0 °C | Condition: Press: 760 Torr
Melting Point:
146-148 °C
Density:
1.125±0.06 g/cm3
InChIKey:
METKIMKYRPQLGS-UHFFFAOYSA-N
InChI:
1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
Canonical SMILES:
CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
1.Investigation of Biowaivers for Immediate Release Formulations Containing BCS III Drugs, Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride, Using Dissolution Testing.
Reddy NH1, Patnala S2, Kanfer I3. AAPS PharmSciTech. 2016 Apr 1. [Epub ahead of print]
The dissolution of several products containing Biopharmaceutical Classification System (BCS) class III drugs, acyclovir, atenolol, and ciprofloxacin hydrochloride, listed in the WHO essential drug list (EDL), was tested and compared with their respective comparator pharmaceutical products (CPPs) marketed in South Africa and India. US Pharmacopeia (USP) buffers of pH 1.2, 4.5, and 6.8 were used as dissolution media and tested using USP apparatus 2 at 75 rpm and 900 ml. Nine acyclovir products were tested, and only three dissolved very rapidly in all media; i.e., they showed a release of >85% in 15 min. Eight atenolol products tested were all very rapidly dissolving in all three pH media. Ten ciprofloxacin hydrochloride products were tested, and the results showed that only five products met the WHO biowaiver criteria. This study indicates that not all marketed products containing the same BCS III active pharmaceutical ingredient (API) in similar strength and dosage form are necessarily in vitro equivalent as per the WHO biowaiver criteria.
2.Formulation and evaluation of atenolol floating bioadhesive system using optimized polymer blends.
Siddam H1, Kotla NG2, Maddiboyina B3, Singh S4, Sunnapu O2, Kumar A1, Sharma D5. Int J Pharm Investig. 2016 Apr-Jun;6(2):116-22. doi: 10.4103/2230-973X.177832.
INTRODUCTION: Oral sustained release gastro retentive dosage forms offer several advantages for drugs having absorption from the upper gastrointestinal tract to improve the bioavailability of medications which have narrow absorption window. The aim of the study was to develop a floating bioadhesive drug delivery system exhibiting a unique combination of floatation and bioadhesion to prolong the residence in the stomach using atenolol as a model drug.
3.Chemical and biochemical characterization and in vivo safety evaluation of pharmaceuticals in drinking water.
Gaffney VJ1, Mota-Filipe H1,2, Pinto RA1,3, Thiemermann C1,4, Loureiro M5, Cardoso VV5, Benoliel MJ5, Almeida CM1,6. Environ Toxicol Chem. 2016 Apr 8. doi: 10.1002/etc.3451. [Epub ahead of print]
The water constituents that are currently subject to legal control are only a small fraction of the vast number of chemical substances and microorganisms that may occur in both the environment and in water resources. The main objective of this work is to study the health impact resulting from exposure to a mixture of pharmaceuticals that have been detected in tap water at low doses. Analysis of atenolol, caffeine, erythromycin, carbamazepine and their metabolites in blood, urine, feces, fat tissue, liver and kidney after exposure to a mixture of these pharmaceuticals in treated drinking water were performed. The effects of this exposure were assessed in rats by measuring biochemical markers of organs injury or dysfunction. Simultaneously, the selected pharmaceuticals were also quantified in both physiological fluids and organ homogenates by liquid chromatography/tandem mass spectrometry (performed in multiple reaction monitoring mode and full scan mode).
4.Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis.
Guerrier K1, Shamszad P2, Czosek RJ2, Spar DS2, Knilans TK2, Anderson JB2. Pediatr Cardiol. 2016 Mar 31. [Epub ahead of print]
Supraventricular tachycardia (SVT) is the most frequent form of symptomatic tachyarrhythmia in infants. The purposes of this study were to describe practice patterns of the management of infants hospitalized with SVT and factors associated with 30-day hospital readmission. This was a multi-institutional, retrospective review of the pediatric health information system database of SVT hospitalizations from 2003 to 2013. High-volume centers (HVC) were defined as those at the upper quartile of admissions. Infants with an ICD-9 code of paroxysmal SVT were included. Antiarrhythmics investigated included amiodarone, atenolol, digoxin, esmolol, flecainide, procainamide, propafenone, propranolol, and sotalol. Frequency of antiarrhythmic use based on center volume was the primary end point. Rate of 30-day SVT readmission was the secondary end point. Analysis of factors associated with readmission was assessed by Chi-square analysis and expressed as odds ratio and 95 % confidence interval.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Adrenergic Receptor Products


CAS 29122-68-7 Atenolol

Atenolol
(CAS: 29122-68-7)

Atenolol, with antianginal and antiarrhythmic properties, it is a cardioselective beta-adrenergic blocker and used in hypertension control.

CAS 152520-56-4 Nebivolol

Nebivolol
(CAS: 152520-56-4)

Nebivolol selectively inhibits β1-adrenoceptor with IC50 of 0.8 nM.

CAS 13392-18-2 Fenoterol

Fenoterol
(CAS: 13392-18-2)

Fenoterol, a phenol derivative, is a β2-adrenoceptor agonist and could be used as a bronchodilator and an antiasthmatic.

CAS 13523-86-9 Pindolol

Pindolol
(CAS: 13523-86-9)

Pindolol, an Indole derivative, could be used in the treatment of hypertension and arrhythmia for acting as a 5-HT1A/1B receptor antagonist. IC50: 33nM(Ki).

CAS 51-42-3 Epinephrine Bitartrate

Epinephrine Bitartrate
(CAS: 51-42-3)

Epinephrine Bitartrate is an alpha- and beta-adrenergic receptor stimulator. It can be used for the treatment of asthma and cardiac failure via stimulating the ...

CAS 29110-47-2 Guanfacine

Guanfacine
(CAS: 29110-47-2)

Guanfacine, a selective agonist of α2A receptor, is a sympatholytic drug to treat attention deficit hyperactivity disorder (ADHD) and hypertension. It lowers bo...

CAS 118457-16-2 (-)-Nebivolol

(-)-Nebivolol
(CAS: 118457-16-2)

This active molecular is a β-adrenergic receptor antagonist. Levonebivolol is an enantiomer of Nebivolol which is a β1 receptor blocker with nitric oxide-potent...

CAS 139047-55-5 2-PMDQ

2-PMDQ
(CAS: 139047-55-5)

2-PMDQ, an analog of Ketanserin with beneficial hemodynamic effects in portal hypertensive rats, is a potent and selective α1-adrenoceptor antagonist.

Chemical Structure

CAS 29122-68-7 Atenolol

Quick Inquiry

Verification code

Featured Items